CSTL241220C35000
- 0.74
- -0.06-7.50%
Castle Biosciences Newsroom
Corcept Shares Rise More Than 60% in Three Months: Here's Why
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Castle Biosciences, Inc.'s (NASDAQ:CSTL) Business Is Trailing The Industry But Its Shares Aren't
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx-Melanoma and MyPath Melanoma at the American Society of Dermatopathology 61st Annual Meeting
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why
Castle Biosciences Surpasses 25,000 Test Reports Delivered for Its TissueCypher Barrett's Esophagus Test
Castle Biosciences Is Maintained at Sector Outperform by Scotiabank
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $44
Use of Castle Biosciences' DecisionDx-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings From Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations
Castle Biosciences Price Target Raised to $36 From $28 at KeyBanc
Strong Growth Prospects and Financial Health Support Buy Rating for Castle Biosciences
Castle Biosciences Faces Financial Strain Amid 2024 Loan Covenant Restrictions
Castle Biosciences Insider Sold Shares Worth $273,251, According to a Recent SEC Filing
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $45
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $40